Serious adverse events following immunization and predictors of mortality associated with COVID-19 vaccination in India: a secondary data analysis of nationwide causality assessments.

Q2 Medicine
Therapeutic Advances in Vaccines and Immunotherapy Pub Date : 2025-03-02 eCollection Date: 2025-01-01 DOI:10.1177/25151355251321697
Abin Kulathunkal Rajan, Md Abu Bashar
{"title":"Serious adverse events following immunization and predictors of mortality associated with COVID-19 vaccination in India: a secondary data analysis of nationwide causality assessments.","authors":"Abin Kulathunkal Rajan, Md Abu Bashar","doi":"10.1177/25151355251321697","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Vaccines against COVID-19 were viewed as a way out to the ongoing pandemic and were given the emergency use authorization in India to initiate mass vaccination in January 2021. This study aimed to investigate the serious adverse events following immunizations (AEFIs) reported for COVID-19 vaccines and to identify predictors of mortality among these cases from India.</p><p><strong>Methods: </strong>A secondary data analysis was conducted on the causality assessment reports for the 2708 serious AEFIs published by the National AEFI Committee under the Immunization Division, Ministry of Health and Family Welfare, Government of India. The analysis included all 21 reports published up until May 2023. The primary outcome variable analyzed was the survival/death status of each AEFI case, with various covariates from the published documents considered in the analysis.</p><p><strong>Results: </strong>The majority of the serious AEFIs assessed were either coincidental (1220, 45%) or undetermined/unclassifiable (781, 28.8%). The majority of the serious AEFIs were reported among recipients of Covishield (1891, 69.8%) followed by Covaxin (347, 12.8%). Among these, 1114 (42.1%) died while the remaining 1594 (58.9%) were hospitalized and recovered. Systematically, AEFIs involving the cardiovascular system (696, 31.3%) were the most common, followed by those affecting the respiratory system (288, 13%) and neuropsychiatric system (295, 13.3%) which had a significant association with age (<i>p</i> < 0.001) and gender (<i>p</i> < 0.001). On multivariable analysis, females (<i>p</i> = 0.001), younger age groups (<i>p</i> < 0.001), AEFIs whose causality was determined and classified (<i>p</i> < 0.001), AEFI involving gastrointestinal and neuropsychiatric system (<i>p</i> < 0.001), AEFIs reported from North and Western India (<i>p</i> = 0.001) and those occurring during the winter season (<i>p</i> < 0.05) had significantly lower odds of mortality.</p><p><strong>Conclusion: </strong>Among the cohort of serious AEFIs reported, older age, male sex, undetermined or unclassifiable causality classification, and involvement of the cardiovascular system were associated with significantly higher odds of mortality and require close monitoring following vaccination.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"13 ","pages":"25151355251321697"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11873861/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Vaccines and Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25151355251321697","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Vaccines against COVID-19 were viewed as a way out to the ongoing pandemic and were given the emergency use authorization in India to initiate mass vaccination in January 2021. This study aimed to investigate the serious adverse events following immunizations (AEFIs) reported for COVID-19 vaccines and to identify predictors of mortality among these cases from India.

Methods: A secondary data analysis was conducted on the causality assessment reports for the 2708 serious AEFIs published by the National AEFI Committee under the Immunization Division, Ministry of Health and Family Welfare, Government of India. The analysis included all 21 reports published up until May 2023. The primary outcome variable analyzed was the survival/death status of each AEFI case, with various covariates from the published documents considered in the analysis.

Results: The majority of the serious AEFIs assessed were either coincidental (1220, 45%) or undetermined/unclassifiable (781, 28.8%). The majority of the serious AEFIs were reported among recipients of Covishield (1891, 69.8%) followed by Covaxin (347, 12.8%). Among these, 1114 (42.1%) died while the remaining 1594 (58.9%) were hospitalized and recovered. Systematically, AEFIs involving the cardiovascular system (696, 31.3%) were the most common, followed by those affecting the respiratory system (288, 13%) and neuropsychiatric system (295, 13.3%) which had a significant association with age (p < 0.001) and gender (p < 0.001). On multivariable analysis, females (p = 0.001), younger age groups (p < 0.001), AEFIs whose causality was determined and classified (p < 0.001), AEFI involving gastrointestinal and neuropsychiatric system (p < 0.001), AEFIs reported from North and Western India (p = 0.001) and those occurring during the winter season (p < 0.05) had significantly lower odds of mortality.

Conclusion: Among the cohort of serious AEFIs reported, older age, male sex, undetermined or unclassifiable causality classification, and involvement of the cardiovascular system were associated with significantly higher odds of mortality and require close monitoring following vaccination.

印度免疫接种后的严重不良事件和与COVID-19疫苗接种相关的死亡率预测因素:对全国因果关系评估的二次数据分析
背景:针对COVID-19的疫苗被视为应对当前大流行的一条出路,印度已获得紧急使用授权,于2021年1月启动大规模疫苗接种。本研究旨在调查COVID-19疫苗接种后报告的严重不良事件(AEFIs),并确定印度这些病例的死亡率预测因素。方法:对印度政府卫生和家庭福利部免疫司下属的国家急性呼吸道感染委员会公布的2708例严重急性呼吸道感染的因果关系评估报告进行二次资料分析。该分析包括截至2023年5月发表的所有21份报告。分析的主要结局变量是每个AEFI病例的生存/死亡状态,分析中考虑了来自已发表文献的各种协变量。结果:大多数评估的严重急性脑损伤是巧合的(1220例,45%)或不确定/无法分类的(781例,28.8%)。严重急性脑梗死以服用Covishield者(1891例,69.8%)最多,其次是服用Covaxin者(347例,12.8%)。其中,1114人(42.1%)死亡,其余1594人(58.9%)住院并康复。系统方面,累及心血管系统的aefi(696例,31.3%)最为常见,其次是累及呼吸系统的aefi(288例,13%)和神经精神系统的aefi(295例,13.3%),与年龄(p p = 0.001)、年轻年龄组(p p p = 0.001)和冬季发生的aefi (p p = 0.001)有显著相关性。在报告的严重急性脑梗塞队列中,年龄较大、男性、未确定或无法分类的因果关系分类以及累及心血管系统与死亡率显著升高相关,需要在接种疫苗后密切监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Therapeutic Advances in Vaccines and Immunotherapy
Therapeutic Advances in Vaccines and Immunotherapy Medicine-Pharmacology (medical)
CiteScore
5.10
自引率
0.00%
发文量
15
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信